REG - LungLife AI, INC - Result of Special Meeting

LungLife AIAnnouncement

20/05/2025 17:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250520:nRST4727Ja&default-theme=true

RNS Number : 4727J  LungLife AI, INC  20 May 2025

20 May 2025

 

LungLife AI, Inc.

(the "Company" or "LungLife")

 

Result of Special Meeting

Update on Cancellation and License and Distribution Agreement

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung
cancer, announces that at the Special Meeting held earlier today, both
resolutions put to Stockholders were duly passed.

 

The proxy votes cast in respect of the Resolutions are as follows:

 

 No.  Summary of Resolution                                                           For*        %      Against  %     Withheld**
 1    To authorise, in accordance with Rule 41 of the AIM Rules for Companies, the    18,092,184  95.2%  921,240  4.8%  1,969,934
      cancellation of the admission to trading on AIM of the Common Shares of the
      Company.
 2    To authorise the transaction between the Company and Circulogene Theranostics,  20,983,358  100%   Nil      0%    Nil
      Inc. and the related agreements on the terms and conditions and as described
      in the Circular published by the Company on 29 April 2025.

 

* Includes those votes giving the Chairman discretion.

**A vote withheld is not a vote in law and is therefore not counted towards
the proportion of votes "for" or "against" the Resolutions.

 

Update on the cancellation of admission of the Common Shares to trading on AIM

 

As a result of the passing of the Cancellation Resolution, trading in the
Company's Common Shares on AIM will be cancelled at 7.00 a.m. on 29 May 2025.
Stockholders are therefore reminded that the last day of dealings in the
Company's Common Shares on AIM will be 28 May 2025.

 

Update on Exclusive License and Distribution Agreement with Circulogene
Theranostics.

 

Following the passing of the Agreement Approval Resolution, the Company is
proceeding to seek Completion of the Agreement.  The Company is working with
the relevant stakeholders to satisfy the Required Consents to allow for
Completion and at present the Board anticipates that Completion should take
place in Q2 2025, although this is expected to be following the date of
Cancellation.

 

Further details of the Agreement and the Cancellation, can be found in the
announcement issued by the Company on  29 April 2025 and the Circular which
was sent to Stockholders on 29 April 2025 and is available on the Company's
website at:
https://lunglifeai.com/investors/financial-information-documents-presentations/
(https://lunglifeai.com/investors/financial-information-documents-presentations/)
.

 

Capitalised terms used in this announcement shall have the meanings given to
such terms in the announcement issued by the Company on 29 April 2025 and in
the Circular unless otherwise defined herein.

 

For further information please contact:

 

 LungLife AI, Inc.                   www.lunglifeai.com (https://www.lunglifeai.com/)
 Paul Pagano, CEO                    via investors@lunglifeai.com
 David Anderson, CFO

 Allenby Capital Limited                                                 Tel: +44 (0)20 3328 5656

 Nominated Adviser and Joint Broker                                      info@allenbycapital.com

 Alex Brearley / Lauren Wright - Corporate Finance

 Matt Butlin / Guy McDougall - Equity Sales & Corporate Broking

 Goodbody (Joint Broker)             Tel: +44 (0) 20 3841 6202
 Tom Nicholson / Cameron Duncan

 

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com
(http://www.lunglifeai.com) .

 

Our Purpose is to be a driving force in the early detection to lung cancer.
And our Vision is to invert the 20:80 ratio such that in years to come at
least 80% of lung cancer is detected early.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMURRNRVWUVUAR